Altimmune (ALT) EBITDA (2010 - 2026)
Altimmune (ALT) posted quarterly EBITDA of -$24.2 million for Q1 2026, down 11.13% year-over-year from -$27.3 million in Q1 2025, and up 16.09% quarter-over-quarter from -$28.9 million in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) EBITDA (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported EBITDA for 17 consecutive years, with -$24.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 11.13% year-over-year to -$24.2 million; the TTM figure through Mar 2026 stood at -$96.9 million (up 1.3% YoY), while the FY2025 annual figure was -$94.5 million, up 8.42% from the prior year.
- EBITDA advanced to -$24.2 million in Q1 2026 per ALT's latest filing, from -$28.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$18.0 million in Q2 2023 and bottomed at -$33.6 million in Q4 2023.
- Historically, EBITDA has averaged -$23.9 million across 5 years, with a median of -$23.1 million in 2022.
- On a YoY basis, EBITDA climbed as much as 26.04% in 2024 and fell as far as 48.53% in 2024.
- Altimmune's EBITDA stood at -$23.1 million in 2022, then tumbled by 45.59% to -$33.6 million in 2023, then climbed by 26.04% to -$24.9 million in 2024, then dropped by 16.19% to -$28.9 million in 2025, then advanced by 16.09% to -$24.2 million in 2026.
- Business Quant data shows ALT's EBITDA at -$24.2 million in Q1 2026, -$28.9 million in Q4 2025, and -$20.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Altimmune | 624.02 Mn | 624.02 Mn | - | -26.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.23 Mn |
| Mar 31, 2026 | -24.24 Mn |
| Dec 31, 2025 | -28.89 Mn |
| Sep 30, 2025 | -20.86 Mn |
| Jun 30, 2025 | -22.92 Mn |
| Mar 31, 2025 | -21.82 Mn |
| Dec 31, 2024 | -24.87 Mn |
| Sep 30, 2024 | -24.77 Mn |
| Jun 30, 2024 | -26.75 Mn |
| Mar 31, 2024 | -26.79 Mn |
| Dec 31, 2023 | -33.62 Mn |
| Sep 30, 2023 | -22.54 Mn |
| Jun 30, 2023 | -18.01 Mn |
| Mar 31, 2023 | -21.76 Mn |
| Dec 31, 2022 | -23.09 Mn |
| Sep 30, 2022 | -24.75 Mn |
| Jun 30, 2022 | -20.40 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -23.99 Mn |
| Sep 30, 2021 | -33.20 Mn |